Researchers and companies developing microneedle vaccine patches (skin-applied, pain-minimal arrays) reported encouraging clinical data in 2023–2024 showing tolerability and strong immune responses for measles/rubella and other vaccines — sometimes with thermostability advantages that could change mass-campaign logistics in low-resource settings. The key advantage: dose sparing and simplified storage/administration (no cold chain or trained syringes), making them attractive for routine immunization and outbreak response. Regulators still need full manufacturing standards and long-term safety data; integration into routine care will depend on cost, manufacturing scale-up and clear labelling so the devices aren’t confused with cosmetic tattooing.
Leave a Reply